Reuters2022-01-26
Jan 26 (Reuters) - Moderna Inc said on Wednesday it had dosed the first participant in a mid-stage study testing its Omicron-specific booster vaccine candidate.
The company also reported data showing that neutralizing antibodies against the Omicron COVID-19 variant declined 6.3-fold from peak levels six months after a third booster dose of its vaccine but remained detectable.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.